The collaborative group believes that diagnostic criteria for acute neuropathic pain should provide a framework for research on and treatment of these complex pain conditions.
Investigators conducted a study to determine the optimal vaccination timing and the temporal immunogenicity and safety of a live herpes zoster vaccine among patients post-HSCT.
Researchers’ findings on the incidence rate of herpes zoster among unvaccinated age groups informs new set of recommendations.
Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) is a disorder characterized by marked fatigue, exertion induced malaise, cognitive clouding (or brain fog), impaired academic/work performance, disrupted sleep, and joint/muscle pain.
Varicella zoster virus (VZV) is extremely stable during the varicella replication phase and subsequent establishment of latency in sensory ganglia throughout the body.
Researchers sought to compare the effectiveness and cost-savings of the recombinant subunit zoster vaccine with that of the live attenuated zoster vaccine in individuals aged ≥50 years.
Only 29% of 2016 survey respondents reported that they strongly agreed that the burden of herpes zoster in patients aged 50 to 59 years old is sufficient to make a vaccine important.
Investigators found a decline in pediatric herpes zoster incidence and a significantly lower incidence among vaccinated children.
A 2-dose course of recombinant zoster vaccine decreased the incidence of herpes zoster in adults who had undergone recent autologous hematopoietic stem cell transplantation.
From 2003 to 2014, there was a decrease in herpes zoster incidence among children, with lower incidence rates for varicella-vaccinated versus unvaccinated children.
